Fantastic reading, as expected.
I have confidence in their approach below - which history show is exactly what they did for PhII for Trof - and we all know how that turned out
"In order to accelerate the overall development plan, in parallel with conducting the Phase 2 trials Neuren is executing the additional development work
required to be ready for Phase 3 development. This includes non-clinical toxicity studies to support longer clinical trials and commercial use of the product as well as optimisation of the drug product and drug substance manufacturing arrangements."
Ann: Q4 2023 quarterly activity report, page-2
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$21.64 |
Change
0.920(4.44%) |
Mkt cap ! $2.763B | |||
| Open | High | Low | Value | Volume |
| $20.86 | $21.64 | $20.56 | $19.10M | 890.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 25 | $21.49 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $21.64 | 588 | 2 |
View Market Depth
| Last trade - 16.10pm 31/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$21.48 |
Change
0.920 ( 3.36 %) |
||||
| Open | High | Low | Volume | ||
| $20.87 | $21.61 | $20.55 | 164887 | ||
| Last updated 15.59pm 31/05/2024 ? | |||||
| NEU (ASX) Chart |